305 related articles for article (PubMed ID: 21289283)
21. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
22. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
23. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment.
Wang H; Wang X; Zhou XY; Chen DJ; Li GC; Iliakis G; Wang Y
Cancer Res; 2002 May; 62(9):2483-7. PubMed ID: 11980637
[TBL] [Abstract][Full Text] [Related]
24. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
25. DNA protein kinase-dependent G2 checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells.
Arlander SJ; Greene BT; Innes CL; Paules RS
Cancer Res; 2008 Jan; 68(1):89-97. PubMed ID: 18172300
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
Pan Y; Ren KH; He HW; Shao RG
Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
[TBL] [Abstract][Full Text] [Related]
28. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation.
Gatei M; Sloper K; Sorensen C; Syljuäsen R; Falck J; Hobson K; Savage K; Lukas J; Zhou BB; Bartek J; Khanna KK
J Biol Chem; 2003 Apr; 278(17):14806-11. PubMed ID: 12588868
[TBL] [Abstract][Full Text] [Related]
29. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Mesa RA; Loegering D; Powell HL; Flatten K; Arlander SJ; Dai NT; Heldebrant MP; Vroman BT; Smith BD; Karp JE; Eyck CJ; Erlichman C; Kaufmann SH; Karnitz LM
Blood; 2005 Jul; 106(1):318-27. PubMed ID: 15784732
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells.
Höglund A; Nilsson LM; Muralidharan SV; Hasvold LA; Merta P; Rudelius M; Nikolova V; Keller U; Nilsson JA
Clin Cancer Res; 2011 Nov; 17(22):7067-79. PubMed ID: 21933891
[TBL] [Abstract][Full Text] [Related]
31. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
32. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
33. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Lainchbury M; Matthews TP; McHardy T; Boxall KJ; Walton MI; Eve PD; Hayes A; Valenti MR; de Haven Brandon AK; Box G; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2012 Nov; 55(22):10229-40. PubMed ID: 23082860
[TBL] [Abstract][Full Text] [Related]
35. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
[TBL] [Abstract][Full Text] [Related]
36. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
Ray S; Shyam S; Fraizer GC; Almasan A
Mol Cancer Ther; 2007 Apr; 6(4):1368-78. PubMed ID: 17431115
[TBL] [Abstract][Full Text] [Related]
37. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer.
Xu J; Li Y; Wang F; Wang X; Cheng B; Ye F; Xie X; Zhou C; Lu W
Oncogene; 2013 Feb; 32(8):976-87. PubMed ID: 22469983
[TBL] [Abstract][Full Text] [Related]
38. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
39. Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway.
Wu F; Chen WJ; Yan L; Tan GQ; Li WT; Zhu XJ; Ge XC; Liu JW; Wang BL
Cancer Med; 2016 Feb; 5(2):370-85. PubMed ID: 26714930
[TBL] [Abstract][Full Text] [Related]
40. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.
Xiao Z; Xue J; Gu WZ; Bui M; Li G; Tao ZF; Lin NH; Sowin TJ; Zhang H
Biomarkers; 2008 Sep; 13(6):579-96. PubMed ID: 18671143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]